The Association of the British Pharmaceutical Industry
Medicines are transforming our lives like never before.
We want the UK to be the best place in the world to research, develop and use the medicines and vaccines of the future.
- VALUING AND ACCESSING MEDICINES
- RESEARCH, DEVELOPMENT AND MANUFACTURING
- WORKING IN PARTNERSHIP
- Industry Reputation
- International Policy, Trade & IP
- HEALTH DATA
VALUING AND ACCESSING MEDICINES
Value and Access
Medicines bring huge value to NHS patients. The development of new medicines is uncertain, costly, and involves significant rates of failure. The pharmaceutical industry spends $160 billion per year on research and development.The private sector produces nearly all the medicines and vaccines available to us. Companies need to make a profit – and a return – on global investment in order to maintain investment in the next generation of medicines.
RESEARCH, DEVELOPMENT AND MANUFACTURING
RESEARCH, DEVELOPMENT AND MANUFACTURING
We're helping to build a thriving environment for medicine discovery so the UK can be the best place in the world to research and develop new medicines and vaccines.
WORKING IN PARTNERSHIP
WORKING IN PARTNERSHIP
We have a long-standing positive relationship with the NHS, and a record of facilitate the same across various parties across the Life Sciences sector. We believe in focusing collaboration on where it can add the most value in making innovation as widely available to patients as possible.
Industry Reputation
INDUSTRY REPUTATION
Everywhere, every day someone relies on the results of our work to ensure their health and wellbeing. We are proud of this and are committed to working with a wide range of people - patients, doctors, nurses, regulators and governments - in order to deliver medicines in an ethically responsible way. Patients are at the heart of everything that we do.
International Policy, Trade & IP
INTERNATIONAL, TRADE AND IP
The ABPI is working to ensure that the UK has the best relationship with our international partners for patients, public health and the life sciences sector.
HEALTH DATA
Health data
We aim to harness the UK’s health data to support the efficient design, feasibility, recruitment and conduct of the full range of clinical trials. We are helping the UK make the most of health-related data for future research and development into new medicines.
King’s Fund report - UK underperforming on treatable health conditions
The King’s Fund published their independent report commissioned by the ABPI comparing the NHS to other international health systems. It gives the NHS a mixed bill of health across a range of outcome measures.
Read the King's Fund Report
Industry’s proposals for a new Voluntary Scheme for Pricing, Access and Growth (VPAG)
The Association of the British Pharmaceutical Industry (ABPI) has published the industry’s vision for a new agreement with the government which will deliver for patients, the NHS and the economy.
Read our proposal for the new Voluntary Scheme on branded medicinesLatest news
ABPI welcomes rare diseases research landscape report
The National Institute for Health and Care Research (NIHR) has today published the first Rare Diseases Research Landscape report for the UK.
ABPI response: UK joins Horizon Europe
UK to associate to Horizon Europe through a new agreement with the EU.
Pharmaceutical companies maintain reputation post-pandemic, new research finds
The latest research from the ABPI-Ipsos Attitudes towards pharmaceutical companies in the UK study.
ABPI response to research on the Innovative Medicines Fund
The ABPI has commented on research from the London School of Hygiene and Tropical Medicine (LSHTM) on the Innovative Medicines Fund.
Latest blogs and events
Connecting Life Sciences and Education
A blog post from Andrew Croydon, ABPI Director of Education and Examination Policy and Partnerships
MHRA’s new International Recognition Procedure (IRP): how does it shape up?
The MHRA has introduced a number of regulatory flexibilities for companies to consider when applying for their products to enter the UK market.
Principles for analysis and use of health data by ABPI members
Blog post from Dr Janet Valentine, ABPI Executive Director, Innovation and Research Policy on the principles for responsible health data analysis
Online Workshop on SMC: How to prepare and submit to SMC | 11-12 December 2023
Making high quality, evidence-based submissions to SMC can mean the difference between successful or very limited access to NHS Scotland for medicines.
Key content hubs
The COP26 summit will bring parties together to accelerate action towards the goals of the Paris Agreement and the UN Framework Convention on Climate Change.
As a critical part of the health care community in the UK, the pharmaceutical industry wants to play the biggest possible role in the response to COVID-19.
The ABPI Code of Practice sets out the requirements the industry must comply with and supports companies’ commitment to self-regulation and to operate in a professional, ethical and transparent manner.
The Pharmaceutical Industry in the UK
![Turnover [1]](/media/b10ppsss/40-8bn-turnover.jpg)
![R and D Investment [2]](/media/ouqnhlry/figures-r-d-investment-5-0bn.jpg)
![Gross Value Added (GVA) [4]](/media/fi4hkeqh/figures-gva-14bn.jpg)
Members
Online members portal (ABPI Meetings via Adam.ai)
ABPI members can log in for bespoke content and services.